Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Locally Advanced Pancreatic Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    186 result(s) found for: Locally Advanced Pancreatic Cancer. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-018327-26 Sponsor Protocol Number: 20080686 Start Date*: 2010-06-09
    Sponsor Name:VU University Medical Center
    Full Title: Chemoradiation with gemcitabine in combination with panitumumab for patients with locally advanced pancreatic cancer.
    Medical condition: Inoperable locally advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002992-42 Sponsor Protocol Number: GP06 Start Date*: 2006-09-06
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer.
    Medical condition: Locally advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033611 Pancreatic carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006302-42 Sponsor Protocol Number: 09/H0604/36 Start Date*: 2009-05-13
    Sponsor Name:The University of Oxford
    Full Title: A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II – Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin
    Medical condition: borderline resectable or unresectable pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033611 Pancreatic carcinoma non-resectable PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033600 Pancreatic adenocarcinoma non-resectable LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002973-23 Sponsor Protocol Number: GAP Start Date*: 2013-11-07
    Sponsor Name:Fondazione GISCAD
    Full Title: A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer.
    Medical condition: 124 locally advanced unresectable pancreatic cancer patients will be randomized in a 1:1 ratio to receive abraxane/gemcitabine (arm A) or gemcitabine alone (arm B), as first-line chemotherapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004236-40 Sponsor Protocol Number: I1-GOA-1 Start Date*: 2007-12-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
    Medical condition: advanced metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000682-32 Sponsor Protocol Number: PAUF-I Start Date*: 2022-02-16
    Sponsor Name:Prestige Biopharma Limited
    Full Title: A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer
    Medical condition: Advanced and/or metastatic pancreatic adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003355-56 Sponsor Protocol Number: M18-006 Start Date*: 2015-04-01
    Sponsor Name:OncoMed Pharmaceuticals, Inc.
    Full Title: A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® plus Placebo versus Gemcitabine, Abraxane® plus 1 or 2 Truncated Courses of Demcizumab in Subjects with 1st-Line Metastatic P...
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000461-10 Sponsor Protocol Number: ISRCTN43482138 Start Date*: 2006-08-25
    Sponsor Name:The Royal Liverpool University Hospital NHS Trust
    Full Title: A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a tel...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002074-46 Sponsor Protocol Number: FIONA Start Date*: 2013-08-02
    Sponsor Name:Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”
    Full Title: Multicentre, two-stage, phase 2 study of neoadjuvant FOLFIRINOX followed by chemo-IMRT in patients with locally advanced unresectable pancreatic cancer
    Medical condition: Locally advanced unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001332-35 Sponsor Protocol Number: AX-CL-PANC-PI-0006859 Start Date*: 2017-03-20
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer
    Medical condition: Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001781-32 Sponsor Protocol Number: MAPS Start Date*: 2007-06-14
    Sponsor Name:GISCAD
    Full Title: A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial
    Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must not have been received a first-line chemotherapy. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019588-12 Sponsor Protocol Number: Bay86-9766/14905 Start Date*: 2010-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer
    Medical condition: Pancreatic cancer is the eighth most common cause of cancer-related death worldwide, associated with a 5-year survival rate of 5-6%. A vast majority of patients present with incurable advanced dise...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    16.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    16.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014476-21 Sponsor Protocol Number: CONKO-007 Start Date*: 2013-02-22
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. med. Markus F. Neurath
    Full Title: Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial: Chemoradiation following induction chemotherapy compared with chemo...
    Medical condition: Locally advanced non resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002957-42 Sponsor Protocol Number: EMR200592-001 Start Date*: 2013-08-06
    Sponsor Name:Merck KGaA
    Full Title: A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjec...
    Medical condition: Locally advanced unresectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Completed) PL (Completed) FI (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004519-32 Sponsor Protocol Number: AVANeo1 Start Date*: 2005-11-28
    Sponsor Name:Medical University Vienna, Dept. of surgery
    Full Title: A randomised controlled pilot study of the efficacy of adding bevacizumab to gemcitabine as neoadjuvant treatment for locally advanced non metastatic pancreatic cancer - Neo-Avastin
    Medical condition: locally advanced non-metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005253-22 Sponsor Protocol Number: 1216.10 Start Date*: 2006-07-24
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-...
    Medical condition: patients with unresectable (locally advanced or metastatic) pancreatic cancer, either chemonaive or after first-line chemotherapy with a gemciatbine based regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005147-17 Sponsor Protocol Number: AIO-PAK-0216 Start Date*: 2018-01-30
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
    Medical condition: locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005076-26 Sponsor Protocol Number: SGNTV-001 Start Date*: 2019-04-16
    Sponsor Name:Seagen, Inc.
    Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
    Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033600 Pancreatic adenocarcinoma non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059326 Pancreatic carcinoma stage IV PT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059333 Pancreatic carcinoma stage IVA LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059335 Pancreatic carcinoma stage IVB LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061902 Pancreatic neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010023 Colorectal neoplasms malignant HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005874-24 Sponsor Protocol Number: PEI004/2021 Start Date*: 2022-07-01
    Sponsor Name:Juan Enrique Domínguez Muñoz
    Full Title: Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer
    Medical condition: pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:32:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA